MedTrace Logo

Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders

NCT04630847 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-23

No results posted yet for this study

Summary

This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota transplant following a 6-week treatment with Vancomycin in adult subjects with ASD for treatment of social deficits and language delays.

Conditions

Interventions

BIOLOGICAL

Fecal Microbiota Transplant

FMT utilizing stool from first degree relatives

Sponsors & Collaborators

  • Ventura Clinical Trials

    collaborator UNKNOWN

  • Microbiome Research Foundation

    collaborator OTHER

  • ProgenaBiome

    lead OTHER

Principal Investigators

  • Sabine Hazan, MD · ProgenaBiome

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630847 on ClinicalTrials.gov